You are now subscribed
Your newsletter sign-up was successful
Want to add more newsletters?
Twice daily
MoneyWeek
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
Four times a week
Look After My Bills
Sign up to our free money-saving newsletter, filled with the latest news and expert advice to help you find the best tips and deals for managing your bills. Start saving today!
The pandemic continues to pose near-term risks as new variants of the virus and rising infection rates prompt governments to extend restrictions. However, vaccines and continued monetary and fiscal-policy stimulus bode well for global growth and will be supportive of Japanese equities. Several themes present themselves. Clean energy and environmental-efficiency are areas where Japan has some very competitive companies. Covid-19 has also accelerated trends in e-commerce and digitalisation. As profits recover, companies will prioritise those areas.
Above all, Japan continues to offer a wealth of under-researched mid- and small-cap growth companies, where we typically find better business models and returns on equity (a key gauge of profitability), and management has more incentives in terms of shareholder returns. Active managers like myself, based here in Japan, get the opportunity not only to invest in established global leaders but also to unearth less well-known companies, where lower levels of coverage by analysts can often yield great mispriced opportunities.
NOF: delivering drugs and profits
NOF (Tokyo: 4403) is a diversified chemicals company with strong positions in many niche markets, resulting in stable growth and high profitability. Its core businesses include surfactants (inputs for toiletries and cosmetics) and drug-delivery system (DDS) products, which ensure that a drug’s active ingredient is delivered and absorbed safely in the right part of the body.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
DDS is a crucial component in mRNA technology (a new form of cancer treatment and also the basis of the Pfizer and Moderna vaccines) and other new treatments, and growth in this field benefits NOF as the market leader. While the stock is often overlooked, this is slowly changing as we successfully engage with the company’s new president to improve the group’s environmental, social and governance and disclosure policies.
Mitsui High-tec: motor-core expert powers ahead
Mitsui High-tec (Tokyo: 6966) comprises almost 70% of the global motor-core market, an essential component of power-train motors in electric and hybrid vehicles. The company’s strength lies in its ultra-precision machining and die technology, which is used to create high-quality motor cores and machine tools. Mitsui High-tec is a dominant supplier and it aims to expand its motor-core production capacity sixfold through 2030, a clear sign of confidence in its order backlog. Yet with a market capitalisation of only £1bn and little coverage, this is a name with significant upside potential.
Coconala: an online freelancers’ market
Coconala (Tokyo: 4176) is a unique online freelancing platform that enables users to trade knowledge, skills and experience. We first invested in the company in 2019, when it was unlisted, recognising it as a beneficiary of the many structural changes occurring in Japan’s labour market; we were attracted by its high and sustainable growth rates as well as the high operating leverage of its business.
Coconala recently had a strong debut on the Tokyo Stock Exchange and the value of the our holding increased more than threefold. The success of this investment highlights the benefits of our research on the ground and efforts to find the most attractive opportunities in corporate Japan.
-
Should you buy an active ETF?ETFs are often mischaracterised as passive products, but they can be a convenient way to add active management to your portfolio
-
Power up your pension before 5 April – easy ways to save before the tax year endWith the end of the tax year looming, pension savers currently have a window to review and maximise what’s going into their retirement funds – we look at how
-
Three key winners from the AI boom and beyondJames Harries of the Trojan Global Income Fund picks three promising stocks that transcend the hype of the AI boom
-
RTX Corporation is a strong player in a growth marketRTX Corporation’s order backlog means investors can look forward to years of rising profits
-
Profit from MSCI – the backbone of financeAs an index provider, MSCI is a key part of the global financial system. Its shares look cheap
-
'AI is the real deal – it will change our world in more ways than we can imagine'Interview Rob Arnott of Research Affiliates talks to Andrew Van Sickle about the AI bubble, the impact of tariffs on inflation and the outlook for gold and China
-
Should investors join the rush for venture-capital trusts?Opinion Investors hoping to buy into venture-capital trusts before the end of the tax year may need to move quickly, says David Prosser
-
Food and drinks giants seek an image makeover – here's what they're doingThe global food and drink industry is having to change pace to retain its famous appeal for defensive investors. Who will be the winners?
-
Barings Emerging Europe trust bounces back from Russia woesBarings Emerging Europe trust has added the Middle East and Africa to its mandate, delivering a strong recovery, says Max King
-
How a dovish Federal Reserve could affect youTrump’s pick for the US Federal Reserve is not so much of a yes-man as his rival, but interest rates will still come down quickly, says Cris Sholto Heaton
